In vitro antiviral efficacy of amenamevir against feline herpesvirus 1.

IF 1.1 4区农林科学 Q3 VETERINARY SCIENCES

Journal of Veterinary Medical Science Pub Date : 2025-08-01 Epub Date: 2025-06-24 DOI:10.1292/jvms.25-0086

Aoi Kikuiri, Haruka Nishigaki, Hikaru Fujii, Shumpei Watanabe, Isshu Kojima, Shigeru Morikawa

引用次数: 0

Abstract

Amenamevir (AMNV), a helicase-primase inhibitor, has recently received approval for treating human herpesvirus infections. Herein, we evaluated the efficacy of AMNV against feline herpesvirus 1 (FHV-1) in three different cell lines and compared it with that of acyclovir (ACV) and penciclovir (PCV)-nucleoside analogs currently used against FHV-1 infection. The 50% inhibitory concentrations of AMNV against FHV-1 were comparable to those of ACV in all cell lines tested, although they were 2.0 to 21.0-fold higher than those of PCV. This is the first study to have evaluated the efficacy of AMNV against animal herpesvirus, and the results suggest that AMNV could be a new option for treating FHV-1 infection with a novel mechanism of action.

查看原文本刊更多论文

阿莫那韦对猫疱疹病毒1型的体外抗病毒作用。

解旋酶引物酶抑制剂Amenamevir （AMNV）最近被批准用于治疗人类疱疹病毒感染。在此，我们评估了AMNV在三种不同细胞系中对猫疱疹病毒1型（FHV-1）的作用，并将其与目前用于FHV-1感染的核苷类似物阿昔洛韦（ACV）和penciclovir （PCV）进行了比较。AMNV对FHV-1的50%抑制浓度在所有细胞系中与ACV相当，尽管它们比PCV高2.0至21.0倍。这是第一个评估AMNV对动物疱疹病毒疗效的研究，结果表明AMNV可能是治疗FHV-1感染的一种新的选择，具有新的作用机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Veterinary Medical Science 农林科学-兽医学

CiteScore

2.30

自引率

8.30%

发文量

230

审稿时长

9-18 weeks

期刊介绍： JVMS is a peer-reviewed journal and publishes a variety of papers on veterinary science from basic research to applied science and clinical research. JVMS is published monthly and consists of twelve issues per year. Papers are from the areas of anatomy, physiology, pharmacology, toxicology, pathology, immunology, microbiology, virology, parasitology, internal medicine, surgery, clinical pathology, theriogenology, avian disease, public health, ethology, and laboratory animal science. Although JVMS has played a role in publishing the scientific achievements of Japanese researchers and clinicians for many years, it now also accepts papers submitted from all over the world.